Cargando…
Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response
Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ErbB2 Receptor Tyrosine Kinase 4 (ERBB4) is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116191/ https://www.ncbi.nlm.nih.gov/pubmed/30044378 http://dx.doi.org/10.3390/cancers10080243 |
_version_ | 1783351549038166016 |
---|---|
author | Donoghue, Jacqueline F. Kerr, Lauren T. Alexander, Naomi W. Greenall, Sameer A. Longano, Anthony B. Gottardo, Nicholas G. Wang, Rong Tabar, Viviane Adams, Timothy E. Mischel, Paul S. Johns, Terrance G. |
author_facet | Donoghue, Jacqueline F. Kerr, Lauren T. Alexander, Naomi W. Greenall, Sameer A. Longano, Anthony B. Gottardo, Nicholas G. Wang, Rong Tabar, Viviane Adams, Timothy E. Mischel, Paul S. Johns, Terrance G. |
author_sort | Donoghue, Jacqueline F. |
collection | PubMed |
description | Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ErbB2 Receptor Tyrosine Kinase 4 (ERBB4) is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM. Using RT-qPCR, we quantified mRNA encoding total ERBB4 and known ERBB4 variants in GBM and non-neoplastic normal brain (NNB) samples. Using immunohistochemistry, we characterized the localization of total and phosphorylated ERBB4 (p-ERBB4) and EGFR protein in archived GBM samples and assessed their association with patient survival. Furthermore, we evaluated the effect of ERBB4 phosphorylation on angiogenesis and tumorigenicity in GBM xenograft models. Total ERBB4 mRNA was significantly lower in GBM than NNB samples, with the juxtamembrane JM-a and cytoplasmic CYT-2 variants predominating. ERBB4 protein was ubiquitously expressed in GBM but was not associated with patient survival. However, high p-ERBB4 in 11% of archived GBM samples, independent of p-EGFR, was associated with shorter patient survival (12.0 ± 3.2 months) than was no p-ERBB4 (22.5 ± 9.5 months). Increased ERBB4 activation was also associated with increased proliferation, angiogenesis, tumorigenicity and reduced sensitivity to anti-EGFR treatment in xenograft models. Despite low ERBB4 mRNA in GBM, the functional effects of increased ERBB4 activation identify ERBB4 as a potential prognostic and therapeutic target. |
format | Online Article Text |
id | pubmed-6116191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61161912018-08-31 Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response Donoghue, Jacqueline F. Kerr, Lauren T. Alexander, Naomi W. Greenall, Sameer A. Longano, Anthony B. Gottardo, Nicholas G. Wang, Rong Tabar, Viviane Adams, Timothy E. Mischel, Paul S. Johns, Terrance G. Cancers (Basel) Article Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ErbB2 Receptor Tyrosine Kinase 4 (ERBB4) is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM. Using RT-qPCR, we quantified mRNA encoding total ERBB4 and known ERBB4 variants in GBM and non-neoplastic normal brain (NNB) samples. Using immunohistochemistry, we characterized the localization of total and phosphorylated ERBB4 (p-ERBB4) and EGFR protein in archived GBM samples and assessed their association with patient survival. Furthermore, we evaluated the effect of ERBB4 phosphorylation on angiogenesis and tumorigenicity in GBM xenograft models. Total ERBB4 mRNA was significantly lower in GBM than NNB samples, with the juxtamembrane JM-a and cytoplasmic CYT-2 variants predominating. ERBB4 protein was ubiquitously expressed in GBM but was not associated with patient survival. However, high p-ERBB4 in 11% of archived GBM samples, independent of p-EGFR, was associated with shorter patient survival (12.0 ± 3.2 months) than was no p-ERBB4 (22.5 ± 9.5 months). Increased ERBB4 activation was also associated with increased proliferation, angiogenesis, tumorigenicity and reduced sensitivity to anti-EGFR treatment in xenograft models. Despite low ERBB4 mRNA in GBM, the functional effects of increased ERBB4 activation identify ERBB4 as a potential prognostic and therapeutic target. MDPI 2018-07-25 /pmc/articles/PMC6116191/ /pubmed/30044378 http://dx.doi.org/10.3390/cancers10080243 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Donoghue, Jacqueline F. Kerr, Lauren T. Alexander, Naomi W. Greenall, Sameer A. Longano, Anthony B. Gottardo, Nicholas G. Wang, Rong Tabar, Viviane Adams, Timothy E. Mischel, Paul S. Johns, Terrance G. Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response |
title | Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response |
title_full | Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response |
title_fullStr | Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response |
title_full_unstemmed | Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response |
title_short | Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response |
title_sort | activation of erbb4 in glioblastoma can contribute to increased tumorigenicity and influence therapeutic response |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116191/ https://www.ncbi.nlm.nih.gov/pubmed/30044378 http://dx.doi.org/10.3390/cancers10080243 |
work_keys_str_mv | AT donoghuejacquelinef activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT kerrlaurent activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT alexandernaomiw activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT greenallsameera activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT longanoanthonyb activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT gottardonicholasg activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT wangrong activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT tabarviviane activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT adamstimothye activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT mischelpauls activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse AT johnsterranceg activationoferbb4inglioblastomacancontributetoincreasedtumorigenicityandinfluencetherapeuticresponse |